Musculoskeletal Syndrome of Menopause: Joint Pain, Frozen Shoulder, and What to Do

A patient sat down last month, frustrated. She was a former marathoner, 44 years old, with new bilateral hip pain, a left shoulder she could no longer raise overhead, and three orthopedic opinions that did not add up to a plan. Her MRI showed mild bursitis. PT was helping a little. Nobody had mentioned hormones. Her FSH came back at 38, estradiol at 22. Right phase of life, wrong starting point for treatment. Six weeks into a body-identical hormone protocol plus a structured resistance training plan, the hip pain was 60% better and the shoulder was finally responding to PT. The diagnosis was not bursitis. It was the musculoskeletal syndrome of menopause.

What Is the Musculoskeletal Syndrome of Menopause?

The musculoskeletal syndrome of menopause is a clinical term introduced in a 2024 Climacteric paper by Wright and colleagues, PMID 39077777, to describe the collective musculoskeletal signs and symptoms driven by the loss of estrogen during the menopause transition. The syndrome encompasses generalized joint pain (arthralgia), tendon problems (tendinopathy), accelerated bone loss, muscle loss (sarcopenia), and the inflammation-driven progression of preexisting osteoarthritis. The numbers from the paper and from longitudinal cohort data:

• More than 70% of women experience some musculoskeletal symptom during the perimenopause-to-postmenopause transition.
• About 25% are functionally disabled by these symptoms (loss of work capacity, exercise capacity, or independence).
• Symptoms often start in perimenopause, when estrogen has begun to fluctuate but periods may still be regular.

The takeaway is simple: this is not a fringe finding. It is the most common, least-named musculoskeletal pattern in women in their 40s and 50s.

Why Does Estrogen Loss Cause Joint Pain?

Estrogen loss causes joint pain because estradiol acts on nearly every tissue in the musculoskeletal system. Estrogen receptors sit in bone, cartilage, ligaments, tendons, muscle, and the synovial lining of joints. When estradiol drops, five things happen at once:

1. Inflammation rises. Estradiol is anti-inflammatory. Lower levels permit higher local and systemic inflammation, which lowers the pain threshold across the body.
2. Cartilage and synovium change. Estrogen receptors in cartilage regulate matrix turnover. Their loss accelerates the wear-and-repair imbalance that drives osteoarthritis pain. A March 2025 mechanism review in IJMS details how falling estradiol contributes to knee osteoarthritis pain through inflammation, cellular senescence, and neurotransmitter changes.
3. Tendons and ligaments get less compliant. Estrogen supports collagen production and crosslinking. Lower estradiol shifts the balance toward stiffer, more injury-prone tissue.
4. Bone loss accelerates. The two to three years around the last period are the steepest stretch of bone loss in a typical woman's life.
5. Muscle protein synthesis falls. Sarcopenia (age-related muscle loss) accelerates. Recovery from exercise takes longer. Strength plateaus, then declines.

This is a system-wide signal change. Treating one joint at a time will fail because the floor under every joint has shifted.

Why Is Frozen Shoulder So Common in Perimenopause?

Frozen shoulder (adhesive capsulitis) is so common in perimenopause because the shoulder capsule is a collagen-rich connective tissue that depends heavily on estrogen signaling. When estradiol drops, the capsule becomes more prone to inflammation, fibrosis, and adhesive thickening. The result is the classic three-phase course: a painful "freezing" phase (weeks to months), a stiff "frozen" phase (months), and a slow "thawing" phase (often a year or more). The epidemiology supports the hormone story:

• Frozen shoulder affects 2 to 5% of the population overall.
• About 70 to 75% of frozen shoulder patients are female.
• Peak age is 40 to 60, exactly the perimenopause window.
• A 2022 Duke study by Wittstein and colleagues published in Menopause found that postmenopausal women on hormone replacement therapy had a lower risk of adhesive capsulitis than women not on therapy. Women without HRT were about twice as likely to develop frozen shoulder.
• Diabetes raises frozen shoulder risk to roughly 5 times the baseline, independent of hormones. The combination of perimenopause and diabetes is especially high-risk.

A 2026 follow-up pilot study from the same group published in Climacteric (PMID 41614260) is laying the design groundwork for a definitive randomized trial of HRT as prevention. The evidence is observational so far; the mechanism and the consistency of the association are why most menopause clinicians now treat HRT as a reasonable consideration in this clinical scenario.

Guidance from the Clinic

What Other Signs Point to the Musculoskeletal Syndrome of Menopause?

The musculoskeletal syndrome of menopause produces a recognizable pattern. Any one of these in isolation can be something else. The pattern of two or more, in a woman between 40 and 60, with cycle changes or vasomotor symptoms, points strongly to the syndrome.

• New, generalized joint aches in the 40s, often migrating from joint to joint week to week.
• Morning stiffness lasting under 30 minutes, then loosening (longer stiffness suggests inflammatory arthritis, which needs a different workup).
• Tendinopathy of the rotator cuff, gluteal tendons (lateral hip pain), Achilles, or tennis elbow, with no clear inciting injury.
• Frozen shoulder in one or both shoulders.
• New plantar fasciitis or chronic foot aches.
• Loss of strength that exercise no longer rebuilds the way it used to.
• Acceleration of preexisting osteoarthritis in the knees, hips, or hands.
• New low back or sacroiliac pain that imaging does not fully explain.

These symptoms often arrive before classic menopause signs (hot flashes, night sweats) and before the periods clearly become irregular. Many patients sit with them for years.

What Other Conditions Mimic This?

Several conditions mimic the musculoskeletal syndrome of menopause and must be ruled out before settling on the diagnosis. The workup should include the screening for each.

• Hypothyroidism: produces generalized aches, stiffness, and fatigue. TSH, free T3, free T4, and TPO antibodies.
• Inflammatory arthritis (rheumatoid, psoriatic, lupus, polymyalgia rheumatica): produces longer morning stiffness, symmetric small-joint swelling, or elevated inflammatory markers. Check RF, anti-CCP, ANA, ESR, hs-CRP.
• Vitamin D deficiency and insufficiency: extremely common in Philadelphia winters; vitamin D below 30 ng/mL worsens muscle and bone pain.
• Iron deficiency and anemia: produces fatigue and exertional aches. Ferritin, iron panel, CBC.
• Diabetes and insulin resistance: directly raises tendon and frozen shoulder risk. Fasting insulin, A1C.
• Statin-related myalgia: any new statin or dose change in the last 6 months can produce muscle aches that look hormonal.
• Lyme disease: in Pennsylvania, especially after summer or fall outdoor exposure.
• Fibromyalgia: a separate diagnosis that can coexist with the menopause syndrome and needs its own treatment plan.

This is the work that gets skipped in a 15-minute primary care visit. It is the same work that turns a vague "you're getting older" into a real plan.

What Labs Should I Ask For?

A complete first-pass workup, in my practice, looks like this: Hormones:

• Estradiol (often low or fluctuating)
• Progesterone (luteal phase if cycling; often low or absent in anovulatory cycles)
• FSH and LH
• Total and free testosterone, SHBG, DHEAS
• AMH (helpful for staging)

Thyroid:

• TSH, free T3, free T4, TPO antibodies

Metabolic:

• Fasting insulin and glucose, hemoglobin A1C
• Lipid panel with ApoB

Inflammation, infection, and nutrient panel:

• hs-CRP, ESR
• CBC, ferritin, iron studies
• 25-hydroxy vitamin D, magnesium, B12, omega-3 index

Autoimmune and rheumatology (if pattern suggests):

• ANA, RF, anti-CCP

Lyme (if outdoor exposure in PA spring/summer/fall):

• Lyme IgG/IgM with reflex Western blot

The list is long because the differential is long. The point is to find the actual driver, not to guess.

How Is the Musculoskeletal Syndrome of Menopause Treated?

The musculoskeletal syndrome of menopause is treated by addressing the underlying estrogen loss alongside the specific musculoskeletal problem. The components stack, and almost no patient gets fully better from one component alone.

The Hormonal Foundation

For most patients with confirmed perimenopause or menopause and no contraindications, body-identical hormone therapy is the most direct treatment for the underlying driver. The standard starting protocol:

• Transdermal estradiol (patch or gel). Bypasses the liver, avoids the clotting-factor increase of oral pills.
• Oral micronized progesterone (or transdermal in selected patients). Identical to the body's own molecule. Often taken at night to support sleep.
• Low-dose testosterone when indicated for libido, mood, energy, or muscle preservation.

The framework is well-supported in modern guidelines (the 2022 NAMS position statement being the anchor reference). When started within the so-called "window" (within 10 years of menopause onset or before age 60), the safety profile is favorable for most patients and the musculoskeletal benefits are real.

The Strength and Loading Foundation

Estrogen is one input. The other is mechanical loading. Tendons, muscle, and bone all respond to resistance.

• Resistance training, 2 to 4 sessions per week. Heavy enough to challenge the working muscle group. Compound lifts (squat, deadlift, hinge, press, row) plus targeted accessory work for shoulders, hips, and core.
• Protein, 1.6 to 2.2 g per kg of body weight per day, distributed across 3 to 4 meals with 30 to 40 g of protein at each.
• Zone 2 cardio, 2 to 3 hours per week, in addition to lifting. Supports mitochondrial health and recovery.
• Sleep, 7 to 9 hours. Recovery and tendon repair happen in deep sleep.

Targeted Frozen Shoulder Treatment

For an actual frozen shoulder, the timeline matters more than any single intervention:

• Early "freezing" phase (most painful): pain control, gentle range of motion, avoid forceful stretching. An intra-articular corticosteroid injection can shorten this phase.
• "Frozen" phase (stiff): structured physical therapy focused on capsule mobility. Hydrodilatation (injection of saline plus steroid plus local anesthetic to stretch the capsule) is effective in resistant cases.
• "Thawing" phase: progressive strengthening alongside continued mobility work.
• Surgical capsular release is reserved for cases that fail conservative care over 12 to 18 months.

Hormone therapy, when started early, may shorten the overall course and reduce the chance of the same syndrome on the other side later.

How Fishtown Medicine Approaches the Musculoskeletal Syndrome of Menopause

At Fishtown Medicine, the first visit for new midlife joint pain is 60 to 90 minutes, and the lab panel above is ordered before the patient leaves. The workflow:

1. Full history and exam. Cycle history. Sleep, mood, sweats. Joint-by-joint exam. Skin and hair changes. Family history.
2. One-shot lab order through Quest or LabCorp, billed to insurance where possible.
3. Lab review at 1 to 2 weeks. Walk through results. Confirm or revise diagnosis.
4. Personalized plan. Hormone therapy if indicated and desired. Resistance training program. Nutrition framework. PT referral when the shoulder, hip, or knee needs hands-on work.
5. Re-check labs at 6 to 12 weeks after starting therapy, then every 6 months until stable.
6. Direct text access for titration questions, side effects, or new symptoms between visits.

This is the same continuous-care approach that makes Fishtown Medicine work for everything else. The reason it matters for this syndrome specifically is that the diagnosis is a starting line, not a finish line. Two months of titration with direct access usually beats six months of waiting between appointments.

The Bottom Line

If you are in your 40s and your joints suddenly hurt for no clear reason, or a shoulder is locking up that you cannot explain, the answer is probably not bursitis, fibromyalgia, or "you're getting older." It is probably the musculoskeletal syndrome of menopause, a now-named clinical entity backed by the 2024 Wright et al. Climacteric paper and a growing observational literature on HRT and frozen shoulder. The treatment combines body-identical hormone therapy (when appropriate), resistance training, and targeted physical therapy. It works.

Key Takeaways

• 70% of women experience musculoskeletal symptoms in the menopause transition; 25% are disabled by them.
• The musculoskeletal syndrome of menopause is the name for this pattern (Wright et al., Climacteric 2024).
• Frozen shoulder is roughly 2 to 5% of the population, 70 to 75% female, peaks 40 to 60, and is meaningfully reduced by HRT in observational data.
• A complete workup rules out thyroid, autoimmune, vitamin D, iron, diabetes, and Lyme before settling on the syndrome.
• Treatment stacks: body-identical HRT (when indicated), resistance training, protein, sleep, plus targeted PT for the specific joint.

Scientific References and Sources

1. Wright VJ, Schwartzman JD, Itinoche R, Wittstein J. (2024). "The musculoskeletal syndrome of menopause." Climacteric, 27(5), 466-472. PMID: 39077777.
2. Wittstein J, Ford A, Saltzman EB, et al. (2022). "Is Hormone Replacing Therapy Associated with Reduced Risk of Adhesive Capsulitis in Menopausal Women? A Single Center Analysis." Menopause / abstract published in Orthopaedic Journal of Sports Medicine.
3. Wittstein J et al. (2026). "A preliminary pilot study to address design issues related to research on potential association of hormone therapy and adhesive capsulitis." Climacteric. PMID: 41614260.
4. The 2022 Hormone Therapy Position Statement of The North American Menopause Society. "2022 Hormone Therapy Position Statement." Menopause. 2022;29(7):767-794.
5. The Mechanism by Which Estrogen Level Affects Knee Osteoarthritis Pain in Perimenopause and Non-Pharmacological Measures. (2025). International Journal of Molecular Sciences, 26(6), 2391.

Medical Disclaimer: This article provides clinical context for educational purposes. In the world of Precision Medicine, there is no "one size fits all"; the right plan must be matched to your unique lab work, physiology, and goals. Consult Dr. Ash or your own clinician to determine if a hormonal workup or hormone therapy is appropriate for you, especially if you have a history of breast cancer, blood clots, stroke, or cardiovascular disease.

---

Dr. Ash is a board-certified internal medicine physician at Fishtown Medicine in Philadelphia. For the broader perimenopause picture, see the Perimenopause: The Window of Opportunity pillar article.